Moneycontrol PRO
management interviews
Jump to
24 Results Found
  • Expect Rs 280-285 crore of topline in Sorbitol segment: Gulshan Polyols Oct 13, 2017 04:34 PM IST

    Expect Rs 280-285 crore of topline in Sorbitol segment: Gulshan Polyols

    In an interview to CNBC-TV18, Rajesh Agrawal, CFO of Gulshan Polyols spoke about the latest happenings in the company and his outlook going ahead.

  • Integration costs to continue into FY16: Sun Pharma Jun 01, 2015 01:19 PM IST

    Integration costs to continue into FY16: Sun Pharma

    Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.

  • No plan to merge SPARC with Sun Pharma: Dilip Shanghvi Mar 25, 2015 07:18 PM IST

    No plan to merge SPARC with Sun Pharma: Dilip Shanghvi

    With Sun Pharma-Ranbaxy merger complete, Sun is now India's largest and the world's fifth largest drug maker with combined revenue of USD 5.14 billion

  • See Rs 400cr increase in top line over next few yrs: Hetero Mar 24, 2015 03:29 PM IST

    See Rs 400cr increase in top line over next few yrs: Hetero

    The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.

  • Sun Pharma maintains 13-15% FY15 topline guidance: CFO Feb 18, 2015 02:54 PM IST

    Sun Pharma maintains 13-15% FY15 topline guidance: CFO

    The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, CFO, Sun Pharma.

  • Sun's margins may reduce to 30-32% post merger: Surajit Pal Dec 29, 2014 12:36 PM IST

    Sun's margins may reduce to 30-32% post merger: Surajit Pal

    As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

  • Sun-Ranbaxy: Agency to monitor drug divestment, says CCI Dec 09, 2014 10:59 AM IST

    Sun-Ranbaxy: Agency to monitor drug divestment, says CCI

    In an interview to CNBC-TV18, Ashok Chawla, Chairperson, CCI, said the order on Sun-Ranbaxy merger is final and that the companies could be given additional 4 months in case the product divestment process exceeds 6 months.

  • Merger with Ranbaxy might get delayed: Sun CFO Baldota Nov 14, 2014 11:59 AM IST

    Merger with Ranbaxy might get delayed: Sun CFO Baldota

    The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally.

  • Ranbaxy loses Valcyte exclusivity: An analysis Nov 07, 2014 10:14 AM IST

    Ranbaxy loses Valcyte exclusivity: An analysis

    Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.

  • SC notice to Ranbaxy over adulterated drug; stock sinks 5% Mar 14, 2014 12:27 PM IST

    SC notice to Ranbaxy over adulterated drug; stock sinks 5%

    If a ban is imposed on the cholestoral drug, then Ranbaxy is likely to lose Rs 76 crore in revenues.

  • Need to be watchful of FDA import alert pattern: Dandekar Nov 27, 2013 05:07 PM IST

    Need to be watchful of FDA import alert pattern: Dandekar

    Drug-maker Wockhardt has fallen foul of the US drug regulator once again and this time, the focus is on its Chikalthana plant.

  • 'Doubt Ranbaxy claim that Mohali product filings not hit' Sep 16, 2013 11:16 AM IST

    'Doubt Ranbaxy claim that Mohali product filings not hit'

    The question that needs to be resolved is what exactly is happening in terms of product filing and why is Ranbaxy saying that the product filings have not been impacted, says Vikas Dandekar, India Bureau Chief, PharmAsiaNews.Com.

  • Ailing pharma sector needs uniform drug standards: Ranbaxy Sep 05, 2013 01:32 PM IST

    Ailing pharma sector needs uniform drug standards: Ranbaxy

    Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.

  • 'India to lead global growth; bet on financial services' Jul 13, 2013 04:38 PM IST

    'India to lead global growth; bet on financial services'

    Ajay Piramal says that Indian growth will be higher than the rest of the world soon and adds that the financial services sector is ripe for investment with lucrative returns on offer.

  • 'Adulteration' defined differently in US and India: Ranbaxy Jun 19, 2013 05:58 PM IST

    'Adulteration' defined differently in US and India: Ranbaxy

    Arun Sawhney, managing director and chief executive officer, Ranbaxy continues to deny any wrong doing. He says the USFDA's ban on its products is due to different definitions of what is 'adulterated' in the US and in India.

  • Setting things right, not aware of DCGI probe: Ranbaxy Jun 12, 2013 02:16 PM IST

    Setting things right, not aware of DCGI probe: Ranbaxy

    Agreeing to past misdeeds, Ranbaxy Laboratories says that the company is taking measure to set things right but cliams to be unaware of DCGI probe.

  • Not impacted by Ranbaxy's negative news: Alembic Pharma May 29, 2013 04:38 PM IST

    Not impacted by Ranbaxy's negative news: Alembic Pharma

    Ranbaxy shares declined a further 2 percent on Wednesday morning after a media report said a prominent hospital in Mumbai had advised doctors to stop using the pharma company's drugs.

  • Will end 2012 with higher sales, profits: Ranbaxy Apr 25, 2012 10:07 PM IST

    Will end 2012 with higher sales, profits: Ranbaxy

    Ranbaxy managing director and chief executive Arun Sawhney told CNBC-TV18 that the pharmaceutical company would end fiscal 2012 with better sales and profits

  • Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews Dec 01, 2011 08:56 AM IST

    Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews

    Vikas Dandekar of PharmAsiaNews.com tells CNBC-TV18 that the US FDA approval for Lipitor is definitely going to be a big positive for Ranbaxy.

  • Lipitor is biggest catalyst to Ranbaxy's growth: Expert Nov 30, 2011 11:55 AM IST

    Lipitor is biggest catalyst to Ranbaxy's growth: Expert

    Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that Ranbaxy is most likely set to go ahead with the launch of the generic version of Lipitor, but how much market share it commands needs to be watched.

  • Blocking Ranbaxy's launch of cholesterol drug, where is the logic? Mar 21, 2011 01:05 PM IST

    Blocking Ranbaxy's launch of cholesterol drug, where is the logic?

    The US Foods and Drugs Administration (USFDA) will be sued by the US pharmaceutical company Mylan Inc, for an injunction on the launch of Ranbaxy’s cholesterol treatment drug Aricept, which is a generic version of Pfizer’s Lipitor.

  • Ranbaxy to find a new CFO Jan 27, 2011 08:26 AM IST

    Ranbaxy to find a new CFO

    Ranbaxy CFO, Omesh Sethi has resigned. PharmAsia News India Bureau Chief, Vikas Dandekar, speaks exclusively to CNBC-TV18’s Reema Tendulkar on the exit and what it means for Ranbaxy.

  • What is Lupin's acquisition agenda for the future? Jan 22, 2011 04:27 PM IST

    What is Lupin's acquisition agenda for the future?

    Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.

  • Ranbaxy, Merck call off anti-infectives deal Jan 04, 2011 10:10 PM IST

    Ranbaxy, Merck call off anti-infectives deal

    Drug majors Ranbaxy and Merck have called off a deal that would have seen both the pharma giants join hands to research anti-infectives, reports PharmAsia News. The deal between the two companies was struck in 2008. Ranbaxy was to get milestones and an undisclosed upfront fee as part of the deal.

Sections
ISO 27001 - BSI Assurance Mark